临床试验/NCT03127618

NCT03127618Approved For Marketing不适用

Lorlatinib - PF-06463922

Pfizer0 个研究点开始时间: 2017年4月25日最近更新: 2020年5月15日

相关药物

试验速览

阶段: 不适用
状态: Approved For Marketing
发起方: Pfizer

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Lorlatinib expanded access program

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
接受健康志愿者: 否

入选标准

•Adult, Senior

排除标准

未提供

研究者

发起方

申办方类型

Industry

责任方

Sponsor

相似试验

No Longer Available

18F-Floretyrosine Expanded Access ProgramGlioma (Any Grade) in the Brain

NCT06743100Telix Pharmaceuticals (Innovations) Pty Limited

No Longer Available

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and AdultsHereditary Angioedema (HAE)Angioedema

NCT04583007Shire

No Longer Available

Expanded Access to FosigotifatorVanishing White MatterCree Leukoencephalopathy

NCT06594016AbbVie

Approved For Marketing

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in BrazilThyroid Cancer

NCT03533361Eisai Inc.

进行中（未招募）

AN EXPANDED ACCESS PROGRAM OF TARCEVA (ERLOTINIB) IN PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER

EUCTR2004-000564-28-LTF. Hoffmann-La Roche Ltd5,000